Effect of a Novel, Orally Active Matrix Metalloproteinase-2 and -9 Inhibitor in Spinal and Trigeminal Rat Models of Neuropathic Pain

Aims: To study the effects of a novel matrix metalloproteinase-2 (MMP-2) and MMP–9 inhibitor, AQU-118, on mechanical allodynia in the spinal nerve ligation (SNL) model of neuropathic pain and the chronic constriction injury of the infraorbital nerve (CCI-IoN) model of neuropathic orofacial pain. Methods: Five groups of SNL rats were given daily oral doses of AQU-118 (5, 10, 20 mg/kg), gabapentin (100 mg/kg), or vehicle (0.5% methylcellulose) and then paw withdrawal threshold was measured with von Frey filaments (VF). Three groups of CCI-IoN rats were given daily oral doses of either AQU-118 (40 mg/kg), gabapentin (100 mg/kg), or vehicle (0.5% methylcellulose) and then mechanical allodynia was measured with facial VF and non–reflex-based orofacial stimulation test (OFST) assay. Naïve rats were also tested for the effect of AQU-118 (40 mg/kg) on basal sensitivity to mechanical stimulation/locomotive activity. Results: Mechanical allodynia in SNL rats was attenuated by gabapentin (100 mg/kg) and AQU-118 (in a dose-dependent manner). Mechanical allodynia in CCI-IoN rats was also attenuated (in an equipotent manner) by both AQU-118 (40 mg/kg) and gabapentin (100 mg/kg) as measured by both facial VF and OFST assay. Upon cessation of either AQU-118 or gabapentin, VF-related responses in both models and OFST assay times reverted to levels observed in vehicle-treated rats. No statistically significant change was observed in locomotive activity/paw withdrawal threshold by AQU-118 (40 mg/kg) in naïve rats. Conclusion: The results demonstrated that oral AQU-118 attenuates mechanical allodynia in both neuropathic pain models and with efficacies that mirror gabapentin at the 40 mg/kg dose used in the CCI-IoN model but without effect on basal sensitivity to mechanical stimulation/locomotive activity. These findings support a possible role for MMP-2/-9 in the etiology of neuropathic pain and also suggest that inhibition strategies represent a viable treatment option.

allodynia; inhibitor; matrix metalloproteinase; MMP-2; MMP-9; operant; orofacial pain

1. DeLeo JA, Colburn RW, Nichols M, Malhotra A. Interleukin-6-mediated hyperalgesia/alloynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res 1996;6:695–700.

2. Sweitzer SM, Colburn RW, Rutkowski M, DeLeo JA. Acute peripheral inflammation induces moderate glial activation and spinal IL-1 beta expression that correlates with pain behavior in the rat. Brain Res 1999;829:209–221.

3. George A, Schmidt C, Weishaupt A, Toyka KV, Sommer C. Serial determination of tumor necrosis factor-alpha content in rat sciatic nerve after chronic constriction injury. Exp Neurol 1999;160:124–132.

4. Siebert H, Dippel N, Mader M, Frank W, Bruck W. Matrix metal-loproteinase expression and inhibition after sciatic nerve axotomy. J Neuropathol Exp Neurol 2001;60:85–93.

5. Schafers M, Sorkin LS, Geis C, Shubayev VI. Spinal nerve ligation induces transient upregulation of tumor necrosis factor 1 and 2 in injured and adjacent uninjured dorsal root ganglia in the rat. Neurosci Lett 2003;347:179–182.

6. Mika J, Korostynski M, Kaminska D, et al. Interleukin-1 alpha has antiallodynic and antihyperalgesic activities in a rat neuropathic pain model. Pain 2008;138:587–597.

7. Sommer C, Schmidt C, George A, Toyka KV. A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy. Neurosci Lett 1997;237:45–48.

8. Kawasaki Y, Xu ZZ, Wang X, et al. Distinct roles of matrix metal-loproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008;14:331–336.

9. Kobayashi H, Chattopadhyay S, Kato K, et al. MMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage. Mol Cell Neurosci 2008;39:619–627.

10. Chattopadhyay S, Myers RR, Janes J. Cytokine regulation of MMP-9 in peripheral glia: Implications for pathological processes and pain in injured nerve. Brain Behav Immun 2007;21:561–568.

11. Komori K, Nonaka T, Okada A, et al. Absence of mechanical allodynia and Ab-fiber sprouting after sciatic nerve injury in mice lacking membrane-type 5 matrix metalloproteinase. FEBS Lett 2004;557:125–128.

12. Compound 118. In: Sucholeiki I, Aquilus Pharmaceuticals. Compounds and methods for the treatment of pain and other diseases. US patent 8,765,953. 1 July, 2014.

13. LaBuda CJ, Little PJ. Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat. J Neurosci Methods 2005;144:175–181.

14. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50:355–363.

15. Vos BP, Strassman AM, Maciewicz RJ. Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat’s infraorbital nerve. J Neurosci 1994;14:2708–2723.

16. Christensen D, Gautron M, Guilbaud G, Kayser V. Effect of gabapentin and lamotrigine on mechanical allodynia-like behavior in a rat model of trigeminal neuropathic pain. Pain 2001;93:147–152.

17. Eide PK, Rabben T. Trigeminal neuropathic pain: Patho-physiological mechanisms examined by quantitative assessment of abnormal pain and sensory perception. Neurosurgery 1998; 43:1103–1110.

18. Essick GK. Psychophysical assessment of patients with post-traumatic neuropathic trigeminal pain. J Orofac Pain 2004;18: 345–354.

19. Lascelle DX, Flecknell, PA. Do animals tell us about human pain? Pain Clinical Updates 2010;18(5):1–6.

20. Mogil JS. Animal models of pain: progress and challenges. Nat Rev Neurosci 2009;10:283–294.

21. Vierck CJ, Hansson PT, Yezierski RP. Clinical and preclinical pain assessment: Are we measuring the same thing?Pain 2008,135:7–10.

22. Cha M, Kohan KJ, Zuo X, Ling JX, Gu JG. Assessment of chronic trigeminal neuropathic pain by the orofacial operant test in rats. Behav Brain Res 2012;234:82–90.

23. Zuo X, Ling JX, Xu GY, Gu JG. Operant behavioural responses to orofacial cold stimuli in rats with chronic constrictive trigeminal nerve injury: Effects of menthol and capsazepine. Mol Pain 2013;9:28.

24. Fehrenbacher JC, Henry MA, Hargreaves K. US provisional patent application 61/235,590. 20 August, 2009.

25. Harden N, Cohen M. Unmet needs in the management of neuropathic pain. J Pain Symptom Manage 2003,25(Suppl 5): S12–S17.

26. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; Pursue analgesic success. BMJ 2013,13(346):1–6.

27. Benyamin R, Trescot AM, Data S, et al. Opioid complications and side effects. Pain Physician 2008;11(2 Suppl):S105–S120.

28. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev 2013 Aug 29;8: CD006146:1–62.

29. Nightingale S. The neuropathic pain market. Nat Rev Drug Discov 2012,11:101–102.

30. Wright JW, Harding J. Contributions of matrix metalloproteinases to neural plasticity, habituation, associative learning anddrug addiction. Neural Plast 2009;2009:579382. Epub 2010 Feb 10.

31. Brown TE, Forquier MR, Cocking DL, et al. Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference. Learn Mem 2007;14:214–223.

32. Liu WT, Huan Y, Liu YP, Song AA, Barnes B, Song XJ. Spinal matrix metalloproteinase-9 contributes to physical dependence on morphine in mice. J Neurosci 2010;30:7613–7623.

33. Liu YC, Berta T, Liu T, Tan PH, Ji RR. Acute morphine induces matrix metalloproteinase-9 up-regulation in primary sensory neurons to mask opioid-induced analgesia in mice. Mol Pain 2012;8:19.

34. Sucholeiki I [inventor]. Morphine tolerance and naloxone- precipitated morphine withdrawal mouse studies. In: Compounds and Methods for the Treatment of Pain and Other Diseases. Patent Cooperation Treaty/World International Property Organization. WO 2012/118498 A1 (7 Sept 2012).

35. Imamura K, Takeshima T, Fusayasu E, Nakashima K. Increased plasma matrix metalloprtoteinase-9 levels in migraneurs. Headache 2008;48:135–139.

36. Leppert D, Hughes P, Huber S, et al. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Neurology 1999; 53:62–70.

37. Gurer G, Erdem S, Kocaefe C, Ozguc M, Tan E. Expression of matrix metalloproteinases in vasculitic neuropathy. RheumatolInt 2003;24:255–259.

38. Signorelli SS, Malponte G, Libra M, et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med 2005;10:1–6.

39. Thrailkill K, Bunn RC, Moreau CS, et al. Matrix metallopro-teinase-2 dysregulation in type 1 diabetes. Diabetes Care 2007;30:2321–2326.

40. Yossef M, Megahed H, Tawfik S, et al. Matrix metalloprotein-ase-2 as a marker of microvascular complications in children and adolescents with type 1 diabetes mellitus. Macedonian J Med Sci 2011;4:81–88.